PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23391113-1	2013	Somatostatin analogs (SA) are the standard of care for controlling symptoms of patients with functional gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs).	sa	22-24	somatostatin	Homo sapiens	0-12	
28993415-3	2018	OBJECTIVE: To evaluate the effects of targeting either IGF-I or GH during somatostatin analogue (SA) treatment.	sa	97-99	somatostatin	Homo sapiens	74-86	
18852531-1	2008	CONTEXT: Development of gallstones (GS) is reported during the use of somatostatin analogs (SA) that are at present the mainstay for the medical treatment of acromegaly.	sa	92-94	somatostatin	Homo sapiens	70-82	
21079388-1	2011	INTRODUCTION: It has been reported in some series that gsp+ somatotropinomas are more sensitive to somatostatin analogues (SA) and dopamine"s actions which may be related to their somatostatin receptor (SSTR) and dopamine receptor (DR) profile.	sa	123-125	somatostatin	Homo sapiens	99-111	
21079388-1	2011	INTRODUCTION: It has been reported in some series that gsp+ somatotropinomas are more sensitive to somatostatin analogues (SA) and dopamine"s actions which may be related to their somatostatin receptor (SSTR) and dopamine receptor (DR) profile.	sa	123-125	somatostatin	Homo sapiens	180-192	
20813787-2	2010	OBJECTIVE: To compare traditional and novel biomarkers and health status in patients with acromegaly treated with either surgery alone or somatostatin analog (SA).	sa	159-161	somatostatin	Homo sapiens	138-150